Skip to content
NewsBlazeAU – Lifestyle
Author:
Ascelia Pharma
Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program
November 9, 2026
Quarterly Report Q3 2026: Orviglance(R) Update Following FDA Type A Meeting
November 5, 2026
Ascelia Pharma Provides Orviglance(R) Update Following FDA Type a Meeting
October 11, 2026
Ascelia Pharma Announces Publication of Orviglance Clinical Study in Journal of Magnetic Resonance Imaging
September 24, 2026
Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA
September 10, 2026
Focus on The Path Forward for Orviglance
August 20, 2026
Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026
August 17, 2026
Ascelia Pharma Announces Organizational Changes and a Reduced Cost Base
July 15, 2026
Ascelia Pharma Provides Orviglance Update
July 12, 2026
Ascelia Pharma Provides Update on the Orviglance NDA
July 3, 2026
1
2
Next Page
→